ReviewAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2020
A contemporary look at allergic conjunctivitis.
Review in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Impact of particulate matter and air pollution on ocular surface disease: A systematic review of preclinical and clinical evidence.The ocular surface · 2025Pooled it
- Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial.Japanese journal of ophthalmology · 2024Trial
- Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.Eye (London, England) · 2024Trial
- Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Emerging RNA-Based Therapeutic Strategies for Inflammatory Ophthalmic Disorders of the Anterior Segment: Mechanistic Insights and Translational Potential.ACS pharmacology & translational science · 2026Review
- An interdisciplinary framework for management of ocular allergy: Integrating the allergist in clinical practice.Indian journal of ophthalmology · 2026Review
- Article
- Reproxalap - A Novel Treatment Option for Allergic Conjunctivitis - A Comprehensive Narrative Review.Health science reports · 2026Article
- Corneal tomographic and densitometric characteristics in children with allergic conjunctivitis: a comparative pentacam AXL study.BMC ophthalmology · 2026Article
- Analysis of corneal biomechanical characteristics and clinical correlations in children with dust mite-allergic conjunctivitis.Scientific reports · 2026Article
- Seasonal variations and environmental factors associated with allergic ocular surface disease: A prospective observational study of clinical presentation patterns in South Asian region.International ophthalmology · 2026Observational
- Time-series analysis of pollen concentration effects on allergic conjunctivitis healthcare visits in Beijing, 2023-2024.Frontiers in public health · 2026Article
- Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis.Frontiers in medicine · 2026Article
- Where eye meets body part 1: uniting allergy pathways in ocular and nasal disease - IgE on the offense.Current opinion in allergy and clinical immunology · 2025Review
- Prevalence of ocular allergy among adults in Trinidad and Tobago: A cross-sectional study.International ophthalmology · 2025Article
- Article
- The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study.Scientific reports · 2025Article
- Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis.Postepy dermatologii i alergologii · 2024Review
- Ophthalmic Formulations for the Treatment of Allergic Conjunctivitis and Their Effect on the Ocular Surface: A Review of Safety and Tolerability Assessments in Clinical Trials.Journal of clinical medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic eye disease is common, yet often overlooked in North America. In the U.S., up to 40% of the population is deemed to be affected and this number is growing. Symptoms and signs of ocular allergy can lead to decreased productivity and negatively impact quality of life (QoL). Various treatment options exist to achieve symptom control. For allergic conjunctivitis, ophthalmic agents include antihistamines, mast cell stabilizers, dual-activity agents, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and some off-label treatments. Immunotherapy is recommended as a therapeutic option. This review provides a summary of the forms of ocular allergies, with a focus on symptoms and signs, impact on QoL, physical examination, diagnosis and therapeutic options of allergic conjunctivitis. Through multidisciplinary collaborations, a simplified algorithm for the treatment of allergic conjunctivitis is proposed for Canadian clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.